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Annexin A5 prevents amyloid-β-
induced toxicity in choroid plexus: 
implication for Alzheimer’s disease
Fernando Bartolome  1,2,12 ✉, Agnieszka Krzyzanowska2,12, Macarena de la cueva1,2, 
Consuelo Pascual2, Desiree Antequera1,2, Carlos Spuch3, Alberto Villarejo-Galende1,2,4, 
Alberto Rabano5, Juan fortea1,6,7, Daniel Alcolea  1,6,7, Alberto Lleo  1,6,7, Isidro ferrer  1,8,9, 
John Hardy10, Andrey Y. Abramov11 & Eva carro  1,2 ✉
In Alzheimer’s disease (AD) amyloid-β (Aβ) deposits may cause impairments in choroid plexus, a 
specialised brain structure which forms the blood–cerebrospinal fluid (CSF) barrier. We previously 
carried out a mass proteomic-based study in choroid plexus from AD patients and we found several 
differentially regulated proteins compared with healthy subjects. One of these proteins, annexin A5, 
was previously demonstrated implicated in blocking Aβ-induced cytotoxicity in neuronal cell cultures. 
Here, we investigated the effects of annexin A5 on Aβ toxicity in choroid plexus. We used choroid 
plexus tissue samples and CSF from mild cognitive impairment (MCI) and AD patients to analyse Aβ 
accumulation, cell death and annexin A5 levels compared with control subjects. Choroid plexus cell 
cultures from rats were used to analyse annexin A5 effects on Aβ-induced cytotoxicity. AD choroid 
plexus exhibited progressive reduction of annexin A5 levels along with progressive increased Aβ 
accumulation and cell death as disease stage was higher. On the other hand, annexin A5 levels in CSF 
from patients were found progressively increased as the disease stage increased in severity. In choroid 
plexus primary cultures, Aβ administration reduced endogenous annexin A5 levels in a time-course 
dependent manner and simultaneously increased annexin A5 levels in extracellular medium. Annexin 
A5 addition to choroid plexus cell cultures restored the Aβ-induced impairments on autophagy flux and 
apoptosis in a calcium-dependent manner. We propose that annexin A5 would exert a protective role in 
choroid plexus and this protection is lost as Aβ accumulates with the disease progression. Then, brain 
protection against further toxic insults would be jeopardised.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia 
in elderly1,2. The imbalance between amyloid-β (Aβ) peptide generation from amyloid precursor protein3 and 
clearance, induces its accumulation, aggregation, and deposition in the brain, which is thought to be an early 
and main pathogenic event in AD2,4. Besides accumulation and production in specific parenchyma areas, such 
as hippocampus and cortex, and blood vessels5, Aβ also accumulates in choroid plexus6,7. More specifically it 
was demonstrated that Aβ may be additionally produced and degraded in choroid plexus along with other brain 
areas8–10. Choroid plexus is a monolayer of specialised epithelial cells in the brain ventricles forming the blood – 
cerebrospinal fluid (CSF) barrier. The choroid plexus main function is to produce and secrete CSF (CSF turnover) 
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protecting therefore CSF against external toxic insults. Works carried out by Jean Marie Serot et al., found choroid 
plexus functions of secretion, synthesis, and transport were deteriorated in AD as they observed morphological 
modifications including epithelial atrophy, fibrosis and calcifications of stroma, and thickened basement mem-
brane11. These impairments resulted in lower turnover and CSF stasis, reduced transthyretin levels, a sequestering 
protein synthesised by choroid plexus, and oligomerisation and subsequent accumulation of Aβ (reviewed in12). 
Also, it was demonstrated that Aβ peptides accumulation in choroid plexus is largely responsible for an increased 
level of oxidative stress and cell death7,13. A decreased activity of enzymes involved in oxidative phosphorylation14 
and mitochondrial activity7, may also contribute to impair protein synthesis in choroid plexus. The observed 
decrease in the choroid plexus functional activity would be partially correlated with reduced protein secretion 
and mentioned CSF renewal, which may be involved in the initiation and progression of AD12. Although the 
detailed mechanism of Aβ-induced toxicity in choroid plexus is unclear, perturbation of Ca2+ homeostasis, and 
destabilisation of cellular metabolism by pronounced membrane permeabilisation might likely play an important 
role.
Annexin A5, a Ca2+-regulated, phospholipid-binding protein belongs to the annexins superfamily. This 
protein is abundantly expressed in a wide range of tissues15 with intra- and extracellular locations16. Although 
annexin A5 is extensively used as an indicator of early apoptosis, it was demonstrated that annexin A5 exerts 
protective functions including inhibition of proinflammatory response and improvement of cardiac function 
and survival during endotoxemia in mice17. Also, annexin A5 was found interacting with amyloidogenic proteins 
reducing its toxicity in neurodegenerative diseases and type II diabetes mellitus18. It was also shown annexin A5 
provided protection against Aβ cytotoxicity, and it was proposed that this effect occurs by competitive interaction 
with phosphatidylserine (PS) on the membrane surface19–21.
Annexins are predominately located within the cell, where they mediate cellular processes such as exocytosis 
and endocytosis, membrane structure and generation of lipid rafts, but also extracellular roles such as inflamma-
tion22,23. Particularly, it was reported annexin A5 has antithrombotic properties, reducing vascular inflammation 
and improving endothelial function24–26. Annexin A5 was proposed as biomarker in heart injury27 and also in 
nephrotic syndrome28. Moreover, annexin A5 was associated with various neuropathological conditions. Levels 
of annexin A5 were reported reduced in CSF from Parkinson’s disease (PD) patients29. It was suggested that such 
reduction resulted as consequence of protein consumption during neuronal apoptosis29. Plasma levels of annexin 
A5 were found significantly higher in AD patients compared with healthy individuals30. These works suggested a 
defensive function for annexin A5 in these neurodegenerative diseases based on its interacting role with amyloi-
dogenic proteins, islet amyloid polypeptides and α-synuclein inclusions by reducing the toxicity of these proteins 
and aggregates18.
Using a mass proteomic based study, we previously found changes in annexin A5 protein levels in choroid 
plexus from AD patients31. The present study was focused on examining the potential effects of annexin A5 on Aβ 
toxicity in choroid plexus. For that purpose, we analysed choroid plexus tissue samples and CSF from MCI and 
AD patients, and choroid plexus primary cultures. Here, we show annexin A5 levels in CSF were found progres-
sively increased as the disease stage increased in severity. Simultaneously, annexin A5 levels were found decreased 
with the disease severity in choroid plexus, in opposite way Aβ burden and cell death. We also show that annexin 
A5 may play a protective role in Aβ-induced cell toxicity in choroid plexus by a Ca2+-dependent mechanism.
Results
Annexin A5 levels are increased in CSF from AD patients. By doing a mass proteomic based study, 
we previously found annexin A5 protein levels were differentially expressed in choroid plexus from AD patients 
compared with healthy controls31. Here, we show annexin A5 levels were significantly increased in CSF from MCI 
and moderate AD patients determined by ELISA (Fig. 1a). We also checked by Western Blot annexin A5 levels 
in choroid plexus from brain donors with AD pathology and healthy subjects. Annexin A5 protein levels were 
significantly lower in Braak stages III/IV and V/VI compared with control samples (Fig. 1b). In contrast with our 
previous work31, by increasing the number of samples here we increased the variability losing the significance 
when comparing AD subjects (stages I-II) with control. When comparing last AD stages with controls, variability 
was reduced, and results reflect a significant reduction in annexin A5 levels in advanced AD stages compared 
with aged-matched control subjects. Together, these results could suggest annexin A5 levels in choroid plexus 
progressively are reduced starting at early AD clinical stages.
Aβ-related choroid plexus cell death. AD-related pathology was confirmed analysing the Aβ load in 
choroid plexus by immunohistochemistry using an anti-Aβ antibody (Fig. 2a). The progressive pattern of Aβ 
accumulation in choroid plexus was estimated using an Aβ42 human specific ELISA kit (Fig. 2b). Aβ42 burden was 
significantly higher at Braak stages III/IV and stages V/VI when compared with control cases (Fig. 2b). The effects 
of Aβ accumulation determined in choroid plexus using a Cell Death Detection ELISA kit resulted in progressive 
increased cell death in AD subjects that was significantly higher at Braak stages V/VI compared with healthy 
donors (Fig. 2c). These results were consistent with the previously reported findings showing deleterious effects 
of Aβ in choroid plexus from AD subjects and the AD transgenic APP/PS1 mouse model7. It is important to note 
that the observed progressive Aβ accumulation and cell death in choroid plexus match with the reduced annexin 
A5 levels (Fig. 1b), more evident at late AD stages (III-VI) (Fig. 2d).
Aβ induces Annexin A5 release outside choroid plexus cells. Annexin A5 may be secreted extracel-
lularly and increased annexin A5 levels were previously found in the supernatant of Aβ42-treated neuronal cells32. 
Hence, we asked if changes in annexin A5 levels between choroid plexus and CSF could be related to Aβ overload 
in choroid plexus. We used rat primary cultures of epithelial choroid plexus cells treated with oligomerised Aβ42 
(10 µM) at 6, 12, 24 and 48 hours. Aβ exposure in choroid plexus cells resulted in reduced annexin A5 protein 
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levels in a time course-dependent manner (Fig. 3a). This reduction was significant compared with untreated 
cells 24 and 48 hours after Aβ treatment (Fig. 3a). Conversely, Aβ induced a time course-dependent increase of 
annexin A5 in the extracellular medium (Fig. 3b). Such annexin A5 increase in supernatant was clearly significant 
24 and 48 hours after Aβ treatment (Fig. 3b).
Annexin A5 restores the Aβ-induced impairments on autophagy. A number of studies demonstrate 
autophagy is disrupted at one point in the progression of AD33,34. This pathway may degrade accumulated aber-
rant proteins and peptides such as Aβ. Results above could suggest that annexin A5 may be beneficial in choroid 
plexus from AD patients; therefore we investigated the effect of annexin A5 on autophagy. Analysis of autophagy 
markers in postmortem tissue from AD and healthy donors by immunoblotting, showed significantly increased 
LC3-II levels in choroid plexus from all AD stages including early AD (Fig. 4a) and significantly increased p62 
levels at Braak stages I-IV (Fig. 4b). These results may suggest both, increased autophagy induction and disrupted 
autophagosome – lysosome fusion35,36. Then we investigated annexin A5 effects on Aβ-disrupted autophagy flux 
in choroid plexus cultures from rats. Cells were treated with and without annexin A5 for 1 hour and then exposed 
Figure 1. CSF and choroid plexus annexin A5 protein levels were differentially expressed in AD patients. (a) 
Scatter plot showing CSF levels of annexin A5 protein in healthy donors and clinically diagnosed MCI and AD 
patients determined by ELISA. Annexin A5 levels in CSF samples were found higher in MCI and AD patients 
compared with controls (*p < 0.05, **p < 0.01; control n = 11; MCI n = 6; Mild AD n = 8; Moderate AD n = 6). 
In all cases, each individual value is shown along with the mean ± SEM per group. (b) Scatter plot showing 
annexin A5 protein levels in choroid plexus from AD and healthy donors. Annexin A5 levels were significantly 
reduced in choroid plexus from Braak stages III/IV and V/VI compared with control samples (*p < 0.05; control 
n = 22; AD I-II n = 21; AD III-IV n = 12; AD V-VI n = 13). In all cases, each individual value is shown along 
with the mean ± SEM per group. Bottom images show representative western blots. These images were cropped 
from full-length blots and they are shown in the Supplementary Information section.
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to oligomerised Aβ42 to avoid extracellular Aβ sequestering by annexin A5, thereby preventing the toxicity. 
Immunoblotting revealed that Aβ42 exposure resulted in significantly elevated LC3-II and p62 levels compared 
with untreated cells suggesting autophagosome accumulation (Fig. 4c,d, respectively). Annexin A5 treatment 
in cells restored the LC3-II and p62 levels being similar to the obtained values in untreated or cells treated with 
annexin A5 only (Fig. 4c,d, respectively). In summary, the above results could indicate annexin A5 abolished the 
Aβ-induced impairments on autophagy in choroid plexus cells.
Annexin A5 protects against Aβ-induced apoptosis. It was previously shown annexin A5 inhibited Aβ tox-
icity in neuronal cell cultures16,17,19,20,34,37. We further investigated annexin A5 effect on Aβ-induced toxicity in choroid 
plexus cells. As Aβ-induced autophagy may precede Aβ-induced toxicity we tested the biological role of annexin A5 
on cell viability carrying out bioactivity assays with choroid plexus cell cultures. Cells were previously treated with and 
without annexin A5 for 1 hour and then exposed to oligomerised Aβ42 (10 µM) for 48 hours (Fig. 5). Aβ42 induced 
25% decrease in cell viability in choroid plexus cultures, as assessed by cell counting kit (CCK) assay, compared with 
control (Fig. 5a). Annexin A5 completely prevented cell loss when was added prior to Aβ42 (Fig. 5a). The reduction in 
Figure 2. Aβ deposits and cell death in choroid plexus from AD patients. (a) Representative micrographs 
showing Aβ deposits in choroid plexus from early and advanced AD cases compared with healthy donors. Scale 
bar = 20 μm. (b) Quantified levels of Aβ burden in choroid plexus from healthy donors compared with AD 
subjects measured by ELISA (Cell Death Detection ELISAPLUS kit, Roche). Scatter plot reveals a progressive 
increase in Aβ levels in choroid plexus samples from AD subjects compared with control group (*p < 0.05; 
control n = 7; AD I-II n = 12; AD III-IV n = 11; AD V-VI n = 8). In all cases, each individual value is shown 
along with the mean ± SEM per group. (c) Cell death analysis in choroid plexus from control and AD patients 
was measured using Cell Death Detection ELISAPLUS kit. Scatter plot shows a significant increase in cell death 
in choroid plexus from advanced AD patients (Braak stages V–VI) compared with control subjects (*p < 0.05; 
control n = 7; AD I-II n = 11; AD III-IV n = 11; AD V-VI n = 8). In all cases, each individual value is shown 
along with the mean ± SEM per group. (d) Representative micrographs showing annexin A5 immunostaining 
in choroid plexus from early and advanced AD cases compared with healthy donors. Scale bar = 20 μm.
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cell viability on choroid plexus cells and the protective role of annexin A5 was studied analysing apoptotic cell death 
using the LIVE/DEAD Viability/Cytotoxicity Kit (Fig. 5b,c). 48 hours after incubation with Aβ42 (10 µM), a significant 
increase of apoptotic cell death in choroid plexus cultures was found (Fig. 5b,c). The presence of annexin A5 attenuated 
the Aβ42-induced apoptosis, recovering the amount of living cells and reducing the cell loss (Fig. 5b,c).
Annexin A5 attenuates Aβ-induced impairments on mitochondrial function and [Ca2+] homeo-
stasis in choroid plexus epithelial cells. Both, apoptosis and autophagy are two cellular processes closely 
linked to mitochondria and mitochondrial health and function is reflected in the ΔΨm. By using the fluores-
cent indicator TMRM, we analysed the ΔΨm (Fig. 6a). This dye accumulates in active mitochondria with intact 
membrane potentials, therefore the more fluorescence, the more mitochondrial health and quality. A significant 
decrease in ΔΨm was observed in Aβ-exposed choroid plexus cells reducing the TMRM signal to 74 ± 3% com-
pared with either untreated or cells treated with annexin A5 (Fig. 6b). Treatment of Aβ-exposed choroid plexus 
cells with annexin A5 prevented the reduction in the ΔΨm as TMRM signal showed similar values to untreated 
cells or cells with annexin A5 (Fig. 6b). Mitochondria are master regulators of Ca2+ homeostasis38 that simulta-
neously is linked to autophagy and apoptotic cell death regulation. Because annexin A5 is a Ca2+ binding protein 
we hypothesised that the protective role of annexin A5 could be related to its Ca2+ binding capacity. This could 
be supported by findings in which was demonstrated Aβ-induced toxicity in neurons involved perturbation of 
Ca2+ homeostasis39. We analysed Ca2+ flux upon physiological Ca2+ stimuli in choroid plexus cells incubated 
for 24 hours with oligomerised Aβ42 in absence or presence of annexin A5 (Fig. 6c). Ca2+ signal was evaluated 
using fura-2. Purinergic receptors in epithelial choroid plexus cells were stimulated with ATP allowing the mas-
sive release of Ca2+ from the endoplasmic reticulum (ER) to the cytosol which was ratiometrically quantified 
(Fig. 6c, top panels). After recovery, mitochondrial Ca2+ uptake was analysed by adding the uncoupler FCCP 
and the amount of Ca2+ was quantified (Fig. 6c, top panels). Upon physiological Ca2+ stimuli, changes in ΔΨm 
were simultaneously analysed using Rh123 and the fluorescence was also quantified (dequench mode, Fig. 6c, 
bottom panels). ATP application to Aβ-treated choroid plexus cells was associated to loss of ΔΨm as Rh123 signal 
increased by 23% before FCCP addition. Annexin A5 treatment to Aβ-incubated choroid plexus cells prevented 
the mitochondrial depolarisation as Rh123 fluorescence did not increase after ATP addition. We found that Aβ42 
incubation resulted in a significantly higher Ca2+ release from the ER in response to ATP in choroid plexus cells 
(Fig. 6d, left panel). Simultaneous incubation with Aβ and annexin A5 restored the ATP-induced Ca2+ release 
from the ER in choroid plexus cells resulting in a smaller Ca2+ signal similar to the obtained in untreated or only 
annexin A5 treated cells (Fig. 6d, left panel). Mitochondrial Ca2+ uptake after FCCP addition was also higher in 
Aβ treated cells compared with untreated or only annexin A5 treated cells (Fig. 6d, right panel). Treatment of 
choroid plexus cells with annexin A5 under Aβ presence restored the mitochondrial Ca2+ uptake reaching similar 
levels of the untreated cell or cells treated with annexin A5 (Fig. 6d, right panel). Together, these results confirmed 
Figure 3. Analysis of intra- and extracellular annexin A5 levels in choroid plexus cultures after Aβ incubation. 
(a) Annexin A5 levels in epithelial choroid plexus cell cultures incubated with oligomerised Aβ42 for 6, 12, 24 
and 48 hours determined by Western blot. Annexin A5 levels are shown as percentage of untreated cells. β-actin 
was used as loading control. Histogram reveals a progressive decrease in annexin A5 levels in cells incubated 
with Aβ42 already significant at 24 hours (upper panel) (**p < 0.01; n = 4). Representative bands of annexin 
A5 protein levels in choroid plexus cells at 0, 6, 12, 24 and 48 hours after Aβ42 addition (bottom panel). These 
images were cropped from full-length blots and they are shown in the supplementary information section. 
In all cases data represents mean ± SEM. (b) Annexin A5 levels in extracellular medium of Aβ42-incubated 
choroid plexus cells for 0, 6, 12, 24 and 48 hours. Histogram shows a progressive increase of annexin A5 levels 
in extracellular medium which is already significant 24 hours after Aβ42 incubation (upper panel) (**p < 0.01; 
***p < 0.001; n = 4). Representative bands of annexin A5 protein levels in extracellular medium at 0, 6, 12, 24 
and 48 hours after Aβ42 addition (bottom panel). This image was cropped from a full-length blot shown in the 
Supplementary Information section. In all cases data represents mean ± SEM.
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annexin A5 exerts its protective role on Aβ-induced autophagy and apoptotic cell death in choroid plexus in a 
Ca2+-dependent manner controlled by mitochondria.
Figure 4. Impaired autophagy in AD choroid plexus. (a,b) LC3-II (A) and p62 (b) protein levels in choroid 
plexus from healthy donors and AD patients from I, II, III, IV, V and VI Braak stages determined by Western 
blot. β-actin was used as loading control and data are shown as percentage of untreated cells. (a) Scatter plot 
indicates that autophagic marker LC3-II is significantly increased at early AD stages (Braak I-II). (b) p62 is 
significantly increased at early (Braak I-II) and mid (Braak III-IV) AD stages but decreased at late AD stages 
(Braak V-VI). Representative Western blot showing LC3-II (a) and p62 (b) levels in choroid plexus samples 
from healthy donors, and AD are shown. These images were cropped from full-length blots and they are 
shown in the Supplementary Information section. (*p < 0.05, **p < 0.01, ***p < 0.001; control n = 19; AD I-II 
n = 17; AD III-IV n = 12; AD V-VI n = 13). In all cases, each individual value is shown along with the mean ± 
SEM per group. (c,d) LC3-II (c) and p62 (d) protein levels in epithelial choroid plexus cell cultures incubated 
with and without oligomerised Aβ42 (10 μM) for 24 hours under presence or absence of annexin A5 (15μg/
ml). β-actin was used as loading control and data are shown as percentage of untreated cells. (c) Autophagic 
marker LC3-II is significantly increased upon Aβ42 incubation compared with untreated or annexin A5-treated 
cells. Annexin A5 co-incubation restored the Aβ42-increased autophagic markers levels similar to untreated 
cells. (d) Autophagic marker p62 is significantly increased upon Aβ42 incubation compared with untreated or 
annexin A5-treated cells. Annexin A5 co-incubation restored the Aβ42-increased autophagic markers levels 
similar to untreated cells. Representative Western blot showing LC3II (c) and p62 (d) levels in epithelial choroid 
plexus cell cultures are shown. These images were cropped from full-length blots and they are shown in the 
Supplementary Information section. (**p < 0.01 versus untreated cells; ##p < 0.01, ###p < 0.001 versus Aβ42-
treated cells; n = 6). In all cases data represents mean ± SEM.
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Figure 5. Annexin A5 restores the Aβ-induced cell viability reduction and apoptosis. (a) Epithelial choroid plexus 
cell viability after incubation with and without oligomerised Aβ42 (10 µM) for 48 hours in absence or presence of 
annexin A5. A significant decrease in cellular viability was found in Aβ42 incubated cells compared with untreated 
cells or cells treated with annexin A5 only. Co-administration of annexin A5 (15 µl/ml) and Aβ42 (10 µM) restored cell 
viability in choroid plexus epithelial cell cultures (*p < 0.05 versus untreated cells; ####p < 0.0001 versus Aβ42-treated 
cells; n = 7). In all cases, data represents mean ± SEM. (b) Apoptotic cell death was analysed using the LIVE/DEAD 
Viability/Cytotoxicity Kit (Molecular Probes). Fluorescent images of epithelial choroid plexus cell culture show living 
cells (green) and apoptotic cells (red). Cells were incubated with and without oligomerised Aβ42 (10 µM), in absence 
and presence of annexin A5 (15 µl/ml). Scale bar = 44 μm. (c) Counting alive (green) and apoptotic (red) cells shows 
that Aβ42 incubation induced a significant increase of apoptotic cells compared with untreated or annexin A5 treated 
cells. Co-administration annexin A5 and Aβ42 reduced the number of apoptotic cells (***p < 0.001 versus untreated 
cells; ##p < 0.01 versus Aβ42-treated cells; n = 4). In all cases, data represents mean ± SEM.
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Figure 6. Annexin A5 restores mitochondrial depolarisation in Aβ-treated choroid plexus cultures in a Ca2+-
dependent manner. (a) Representative images of tetramethyl-rhodamine methylester (TMRM) fluorescence 
used in redistribution mode (40 nM) in choroid plexus cultures incubated with and without oligomerised 
Aβ42 (10 µM), in absence and presence of annexin A5 (15 µl/ml). (b) Annexin A5 restored the Aβ-induced 
mitochondrial depolarisation. Data were normalised to untreated cells and are represented as mean ± SEM 
from at least three independent experiments. (*p < 0.05 versus untreated cells; ##p < 0.01 versus Aβ42-treated 
cells; n = 4). (c) Traces showing changes-over time in fura-2 (upper panels) and simultaneous rhodamine 
123 (Rh123) (bottom panels) fluorescence in choroid plexus epithelial cells upon physiological Ca2+ stimuli. 
Physiological Ca2+ was induced by addition of ATP (100 μM). Following Ca2+ release from ER, FCCP (1 μM) 
was added to obtain the maximal mitochondrial depolarisation allowing mitochondrial Ca2+ release. Upon 
stimulation of choroid plexus cells with ATP, Ca2+ stored in the ER was released and profound mitochondrial 
depolarisation was found in Aβ-incubated cells as shown by the increase in the Rh123 signal (iii). This effect was 
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Discusion
Annexins are widely distributed among tissues and their ubiquitous distribution suggests they have important 
roles in cell biology. In particular, annexin A5 has been found exerting anti-inflammatory, anticoagulant and 
anti-apoptotic functions40–46. In endothelial cells, annexin A5 was able to protect against vascular inflammation 
contributing to protect barrier integrity25. Expression of other annexins, annexin A1, A4 and A6, was described 
in choroid plexus47,48, but little is known about expression and role of annexin A5 in this brain structure. Here 
we report increased annexin A5 levels in CSF from clinically diagnosed MCI and AD patients and simultaneous 
reduced annexin A5 levels in choroid plexus from AD brains. These findings are accompanied by increased Aβ 
overload in choroid plexus related to the disease severity and significantly altered autophagic flux and increased 
cell death at late AD stages. In vitro, we also demonstrate that annexin A5 extracellular release in choroid plexus 
cells could be Aβ-overload dependent. We propose that Aβ in choroid plexus may induce increased autophago-
some accumulation. Such effects result finally in increased cell death and annexin A5 down-regulation. On the 
other hand, annexin A5 protects against Aβ toxicity restoring the Aβ-induced Ca2+ homeostasis dysregulation 
linked to the mitochondrial health and function. Together, our findings suggest that annexin A5 plays a crucial 
role in maintaining physiological protection of blood-CSF barrier that is impaired in AD.
The higher levels of annexin A5 found in CSF from MCI and AD subjects compared with healthy donors 
suggests that secreted annexin A5 may indicate early changes in choroid plexus from these patients. Increased 
annexin A5 levels were also found in plasma from AD patients and the AD transgenic mouse model Tg257632. 
We suggest that choroid plexus epithelial cells contribute to increase the annexin A5 levels in CSF along with 
other sources as neurons. Our results indicate CSF levels of annexin A5 become increased even at early stages of 
disease, including MCI, when Aβ accumulation in the brain becomes evident. This is consistent with other find-
ings observed in neuronal cell cultures, describing increased annexin A5 levels in the supernatant of Aβ42-treated 
cells32.
Aβ deposition in brains of AD patients agrees with the hypothesis suggesting Aβ accumulation as the main 
cause for neuronal cell death1,5,49. Exposure of cells to Aβ peptides cause typical apoptotic cell death50,51, although 
lower Aβ concentrations appear to only affect expression of neuronal apoptotic genes, without directly causing 
apoptosis52,53. Here we show that Aβ accumulation in AD is also present in choroid plexus. This observation was 
found gradually increasing as the disease progresses and is consistent with the increased cell death observed in 
choroid plexus from AD subjects. We demonstrate Aβ overload in choroid plexus cultures induced annexin A5 
reduction in cells and subsequently increased annexin A5 in extracellular medium. Annexin A5 release outside 
cells occurs from the cellular apical compartment as has been demonstrated in epithelial cell cultures46,54. Upon 
Ca2+ stimulation, cytoplasmic annexin A5 is translocated to the plasma membrane while nuclear annexin A5 
is moved to the nuclear membrane, in all cases binding to phosphatidylserine (PS)55. As Aβ also binds PS, both 
annexin A5 and Aβ could exert competitive interaction to each other. Reduced levels of intracellular annexin A5 
result in lower competitive inhibition with Aβ at PS interaction site leading to increasing Aβ-induced cytotox-
icity19. We may suggest Aβ overload in patient choroid plexus could induce annexin A5 drain from these cells, 
hence contributing to the observed increased levels in CSF.
Our experiments show that annexin A5 restores the Aβ-induced autophagic flux impairments in choroid 
plexus cells reducing the Aβ-increased levels of LC3-II and p62. Previous works showed elevated LC3-II and p62 
levels in brains from AD patients at different stages of disease56,57. Here we found an increase in these autophagy 
markers in human choroid plexus suggesting that such increase is due to Aβ overload. In support of this observa-
tion several works showed similar effects increasing autophagy markers after Aβ incubation in human neuroblas-
toma H4 cells58 and in cells overexpressing mutant forms of PSEN2 and APP, both linked to Aβ overproduction 
in AD familial cases59,60. Therefore, we may suggest an induction of autophagy is triggered in choroid plexus due 
to Aβ overload. Then autophagosomes containing Aβ cannot be fused with lysosomes resulting in their accumu-
lation and subsequent increased levels of autophagic markers LC3-II and p62. Apart of the mentioned cellular 
models59,60 this dual effect has been also observed in AD brains showing high autophagy flux. Such increased flux 
would try to maintain low Aβ levels through autophagic clearance but this is followed by impaired autolysosomal 
proteolysis33,34,57,61–63. We found that annexin A5 treatment restored the levels of autophagy markers to similar 
values that those obtained in untreated cells. We suggest the annexin A5 effect on autophagy may work enhancing 
autophagosome – lysosomes fusion allowing lysosomal cargo degradation. This agrees with other observations 
where annexin A5 was proposed stimulating autophagy64. In this work, authors showed that overexpression of 
annexin A5 in HEK293T cells decreased LC3-II levels. They proposed such decrease was produced by the annexin 
A5 effect of increasing the autophagosome conversion into autolysosomes and enhancing lysosomal proteolysis64.
Linked to the protective role on autophagy could be the observation that annexin A5 reduced the number 
of Aβ-induced apoptotic cells. The idea of Aβ-induced cell death is preceded by impaired autophagy was also 
showed by other authors65,66. Further analysis about this connection was discussed by Nixon and Yang where they 
not observed in untreated cells (i) or annexin A5-treated cells only (ii). Annexin A5 treatment prevented the 
mitochondrial depolarisation when Ca2+ stimulus was added (iv). (d) Histograms showing ER Ca2+ (left panel) 
and mitochondrial Ca2+ levels (right panel) after addition of ATP and FCCP respectively as explained above. 
ER Ca2+ in choroid plexus cells incubated with Aβ were higher compared with untreated cells or annexin A5-
treated cells only. Annexin A5 co-treatment restored the Aβ-induced increase of ER Ca2+ levels. Mitochondrial 
Ca2+ in Aβ-incubated choroid plexus cells was significantly higher compared with untreated cells or annexin 
A5-treated cells only. These levels were restored upon co-incubation with annexin A5. Data were normalised 
to untreated cells and are represented as mean ± SEM from at least three independent experiments. 
(****p < 0.0001 versus untreated cells; ####p < 0.0001 versus Aβ42-treated cells; n = 4).
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proposed defects in autophagy promoting apoptotic cell death in neurodegenerative diseases67. This is consistent 
with our results as we observed a reduction in autophagy markers and apoptotic cell death when rat primary 
cultures of epithelial choroid plexus cells were incubated with Aβ in presence of annexin A5. Both, stimulation 
of autophagy and apoptotic cell death are tightly regulated by intracellular Ca2+ levels68,69. On this regard, mito-
chondria play an important role in cells as they control bioenergetics, Ca2+ homeostasis and apoptotic cell death. 
Failures in this regulation have been recognised in neurodegenerative disorders. Here, we show that annexin 
A5 restored the Aβ-induced mitochondrial depolarisation reflected by a reduction in the mitochondrial mem-
brane potential which mirrors the mitochondrial health and function. Therefore, mitochondrial depolarisation 
may indicate altered Ca2+ homeostasis regulation. Indeed, our work show Aβ impaired Ca2+ homeostasis, and 
annexin A5 prevented this effects. Aβ exposure made the choroid plexus cells to increase the ER Ca2+ stores. 
Then, by inducing Ca2+ signal, mitochondrial Ca2+ uptake was higher. Both effects were restored by annexin A5 
incubation. It has been shown Aβ affects intracellular Ca2+ concentration by generating Ca2+ permeable channels 
in plasma membrane of neurons and astrocytes70,71. Works carried out in neuronal cells showed Aβ exposure 
induced Ca2+ homeostasis impairments72–75. In vivo, elevated Ca2+ levels in neuronal cytoplasm were linked to 
Aβ42 accumulation76. The observed protective role of annexin A5 in the Aβ-induced autophagy impairments 
and cell death could be related to its affinity binding preferentially acidic phospholipids in a Ca2+ dependent 
manner22. This could be in line with the observed annexin A5 ability to interact with membrane PS. Through this 
interaction, it was found that annexin A5 protected neuronal cells against Aβ toxicity by competitive inhibition 
as both, Aβ oligomers and annexin A5 showed binding affinity to PS in the cell membrane in a Ca2+-dependent 
manner19,20. In a different scenario, we may also explain the protective role of annexin A5 on Aβ-induced toxicity 
by its Ca2+ chelating capacity decreasing the intracellular Ca2+ concentration. All these observations are consist-
ent with our findings in which we found annexin A5 could have a potential beneficial effect on choroid plexus 
and such effect is lost in AD along with progressive increased Aβ accumulation. This beneficial effect of annexin 
A5 has been proved in other neurodegenerative disorders showing its interaction ability with amyloidogenic 
proteins18.
In summary, we show that levels of annexin A5 in choroid plexus from AD are reduced in late stages of dis-
ease, accompanied by high Aβ levels and cell death and simultaneous increased levels of annexin A5 in CSF. The 
data presented here indicate that annexin A5 protects choroid plexus cells from Aβ-induced autophagic impair-
ments and apoptosis by a Ca2+-dependent mechanism under mitochondrial control.
Material and Methods
All methods were performed following the relevant guidelines and regulations approved by the local ethi-
cal review committee from the Hospital 12 de Octubre Research Institute. Other review committees partially 
involved in the present project were the following: 12 de Octubre Hospital, (Madrid, Spain) and Hospital de la 
Santa Creu i Sant Pau (Barcelona, Spain) review committees for research related to CSF samples; The Institute of 
Neuropathology Brain Bank IDIBELL-Hospital Universitari de Bellvitge (Hospitalet de Llobregat, Spain) review 
committee, The Netherlands Brain Bank (NBB) (Amsterdam, The Nederlands) review committee and Banco 
de Tejidos, Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas, Madrid. Spain) review 
committee for research involving the use of choroid plexus samples from human donors. Informed consent was 
obtained from all participants and/or their legal guardians.
CSF collection. CSF samples (10 ml per subject) from 26 mild cognitive impairment (MCI), 20 mild AD, 
20 moderate AD, and 26 healthy control subjects were collected by lumbar puncture upon informed patient 
consent. All samples were centrifuged at 3000 rpm at 4 °C for 10 min to remove any cell and debris, aliquoted in 
small volumes and stored in low bind polypropylene tubes at −80 °C. Samples were obtained from the Hospital 
12 de Octubre Neurology Service (Madrid, Spain), and Hospital de la Santa Creu i Sant Pau Neurology Service 
(Barcelona, Spain). Subjects were clinically diagnosed as probably having AD according to the National Institute 
on Aging and Alzheimer’s Association (NIA-AA) guidelines77. MCI was diagnosed in patients with cognitive 
impairment that did not fulfil the criteria for dementia78,79. All subjects had mini-mental state examination 
(MMSE) scores available. Inclusion criteria for cognitively normal older individual subjects were MMSE scores 
24–30, no history or clinical signs of neurological or psychiatric disease or cognitive symptoms80. Subjects’ 
Control MCI Mild AD Mod AD
p-value(n = 26) (n = 26) (n = 20) (n = 20)
Age, mean (SD) 70.9 (9.2) 70.7 (7.3) 76.6 (6.5) 78.3 (3.6) 0.01
Sex female, n (%) 14 (53.8%) 15 (57.7%) 11 (55.0%) 10 (50.0%) ns
MMSE, mean (SD) 29.0 (1.2) 24.5 (3.4) 19.3 (4.4) 12.3 (5.2) <0.001
CDR 0 0.5 1 2.3 <0.001
ApoE ε4, % 0% 41.6% 46.1% 40.2% 0.01
CSF Aβ42, mean (sem) 885.2 (105.2) 457.3 (53.0)*** 513.8 (95.9)** 339.1 (46.2)*** <0.001
CSF t-tau, mean (sem) 394.5 (54.6) 534.8 (123.5) 690.4 (73.4)* 982.8 (105.4)** 0.01
Table 1. Demographic and clinical characteristics of CSF donors. MCI: mild cognitive impairment; AD: 
Alzheimer’s disease; Mod: moderate-severe; SD: standard deviation; MMSE: Minimental Status Examination; 
ns: non-significant. # p-value indicates statistical differences between all groups; *p < 0.05, **p < 0.01, 
***p < 0.001, versus control group.
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consent was obtained according to Declaration of Helsinki, and approval came from the research ethics commit-
tee of each responsible institution. Written informed consent was given from all participants or representatives. 
Subject demographic and clinical characteristics are listed in Table 1.
Tissue samples. Post-mortem choroid plexus tissue was obtained from brain donors diagnosed with 
AD and control individuals. Frozen samples were supplied by the Institute of Neuropathology Brain Bank 
IDIBELL-Hospital Universitari de Bellvitge (Hospitalet de Llobregat, Spain), The Netherlands Brain Bank 
(NBB) (Amsterdam, The Nederlands), and Banco de Tejidos, Fundación CIEN (Centro de Investigación de 
Enfermedades Neurológicas, Madrid. Spain). In all cases, post-mortem delays before sampling was between 
3–8 hours. Subjects’ consent was obtained according to the Declaration of Helsinki, and approval came from the 
research ethics committee of each responsible institution. For all cases, written informed consent is available. 
Subjects were selected on the basis of post-mortem diagnosis of AD according to neurofibrillary pathology and 
Aβ plaques. Control cases were considered those without neurological symptoms and lesions in the neuropatho-
logical examination. A total of 70 samples were categorised into four groups, as presented in Table 2.
Choroid plexus cultures. Choroid plexus epithelial cell cultures were prepared as described previously81. 
Choroid plexus were dissected from 3–5-day-old Wistar rats (Charles River, MA, USA). ARRIVA guidelines 
for the care and use of animals were followed. Once disaggregated, choroid plexus epithelial cells were seeded 
at a 4 × 104 cells/cm2 density on laminin-coated plates and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Thermo Fisher Scientific, MA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Thermo 
Fisher Scientific, MA, USA), 2 mM L-glutamine and 1% penicillin/streptomycin (Thermo Fisher Scientific, MA, 
USA) at 37 °C and 5% CO2. After 5–7 days on culture cells reached confluence and they were serum-deprived 
for 2 hours and oligomerised Aβ42 (10 µM; AnaSpec, Inc., San Jose, CA) was added. In the experiments with 
annexin A5 (15 µl/ml; Sigma-Aldrich, St. Louis, USA), this drug was added 1 hour before oligomerised Aβ42, to 
allow annexin A5 enter into the cells and avoiding extracellular sequestering of oligomerised Aβ42. Aβ42 stock was 
previously dissolved in acetic acid 0.1 M. Oligomeric Aβ42 was prepared by incubating a volume of stock solution 
in DMEM at 4 °C for 24 hours prior addition to the cell cultures as previously described82.
Immunohistochemistry. Human choroid plexus tissue was fixed for 24 hours in 4% paraformaldehyde 
(PFA) by immersion. Then, choroid plexus samples were OCT embedded and stored at −80 °C for subsequent 
cryostat sectioning (Leica, Wetzlar, Germany). 20 µm thick sections were processed free-floating for immunohis-
tochemistry. To carry out immunohistochemistry for Aβ deposits, brain slices were 20 min pre-incubated with 
88% formic acid and immunolabeled with mouse anti-Aβ antibody (1:500, MBL, Nagoya, Japan). After overnight 
incubation, primary antibody staining was revealed using the avidin-biotin complex method (VECTASTAIN 
Elite ABC Kit, Vector Laboratories, Burlingame, CA) and 3,3′-diaminobenzidine chromogenic reaction (Vector 
Laboratories, Inc). Images were captured using a light microscope (Zeiss microscope; Carl Zeiss Microimaging, 
GmbH, Oberkochen, Germany).
ELISA. Levels of human endogenous Aβ42 in choroid plexus fractions from human subjects were determined 
with human specific ELISA kit (Innotest β-amyloid1–42, Innogenetics, Ghent, Belgium), according to the manu-
facturer’s instructions. Prior to tissue homogenisation, endothelial vessels were removed in order to have pure 
choroid plexus epithelium. Obtained data were normalised to protein content.
DNA fragmentation undergoing apoptosis was detected in choroid plexus tissue from human subjects with a 
Cell Death Detection ELISAPLUS kit (Roche, Basel, Switzerland). According to the manufacturer’s instructions, 
unfixed frozen tissue was incubated with incubation buffer (lysis buffer provided in the kit) and tissue lysates were 
transferred to a streptavidin-coated 96 well microplate and allowing nucleosomes to interact with monoclonal 
antibodies: antihistone (biotin-labeled) and anti-DNA (peroxidase-conjugated). Finally, the amount of coloured 
product was determined using a microplate reader.
Annexin A5 levels in CSF from human subjects were determined with specific human ELISA kit (Abcam, 
Cambridge, UK). Briefly, CSF samples were added to the pre-coated wells, followed by the antibody mix. Finally, 
the signal intensity was measured at 450 nm using a microplate reader.
Western blot. Conditional medium from choroid plexus cultures was collected and protease and phos-
phatase inhibitor cocktails (Roche, Basel, Switzerland) were added. Choroid plexus tissue and cultured choroid 
plexus epithelial cells were homogenised in lysis buffer (50 mM Tris/HCl buffer, pH 7.4 containing 2 mM EDTA, 
0.2% Nonidet P-40, 1 mM PMSF, protease and phosphatase inhibitor cocktails – Roche, Basel, Switzerland), and 
centrifuged for 10 min at 14000 rpm. The supernatant was recovered and stored at −80 °C. Protein content from 
cell lysates, and extracellular medium was determined with the BCA method (Thermo Fisher Scientific, MA, 
USA). Equal amount of protein (20 µg per lane) were separated by SDS-PAGE (4–12%) and transferred onto 
Control AD I-II AD III-IV AD V-VI
p-value(n = 22) (n = 21) (n = 14) (n = 13)
Age, mean (SD) 71.2 (10.0) 69.4 (9.9) 78.9 (7.7) 78.3 (6.6) <0.001
Sex female, n (%) 9 (40.9%) 7 (33.3%) 6 (42.9%) 6 (46.2%) ns
Table 2. Demographic and clinical characteristics of choroid plexus donors. AD I-VI: Alzheimer disease-
related changes, stages of Braak and Braak; SD: standard deviation; ns: non-significant.
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polyvinylidene difluoride (PVDF) membranes (Millipore, MA, USA). For human choroid plexus tissue homoge-
nates 25 µg of protein were loaded. Non-specific bindings were blocked by incubation in 5% non-fat milk in 
Tris-buffered saline (100 mM NaCl, 10 mM Tris, pH 7.4) containing 0.1% Tween (TTBS) for 1 hour at room tem-
perature. Afterwards, membranes were 4 °C incubated overnight with mouse anti-annexin A5 antibody (ab54775, 
1:1000; Abcam, Cambridge, UK), rabbit monoclonal anti-p62 antibody (ab91526, 1:20000; Abcam, Cambridge, 
UK), and rabbit polyclonal anti-LC3 antibody (NB100–2220, 1:1000; Novus, CO, USA). Protein loading was 
monitored using a mouse monoclonal antibody against β-actin (A1978, 1:10000; Sigma-Aldrich, St. Louis, USA). 
Membranes were then incubated for 1 hour in the appropriate horseradish peroxidase-conjugated secondary 
antibodies (1:2000; Dako, CA, USA), and immunocomplexes were revealed by an enhanced chemiluminescence 
reagent (ECL Clarity; Bio Rad, CA, USA). Densitometric quantification was carried out with Image Studio Lite 
5.0 software (Li-COR Biosciences, NE, USA). Protein bands were normalised to β-actin levels and expressed as 
percentage of the control group.
Bioactivity and cell death quantification. In vitro, cell viability was assessed using Cell Counting Kit-8 
(CCK-8 assay, Sigma, St. Louis, USA) according manufacturer’s instructions. Briefly, primary cultures of choroid 
plexus epithelial cells were incubated 48 hours with and without oligomerised Aβ42 (10 µM) and treated with or 
without annexin A5 (15 µl/ml). Then, CCK-8 solution was added, and absorbance was measured 1 hour later at 
450 nm using a microplate reader.
Cell death was assessed 48 hours after incubation with and without both, oligomerised Aβ42 (10 µM) and 
annexin A5 (15 µl/ml) using the LIVE/DEAD Viability/Cytotoxicity Kit (Molecular Probes, Thermo Fisher 
Scientific, MA, USA). Fixed cells were labelled with propidium iodide. Healthy cells were recognised by their 
morphology and green staining, whereas propidium iodide-positive red cells (with condensed choromatin) were 
scored as apoptotic. Resulting images were taken using a fluorescence microscopy (Zeiss microscope; Carl Zeiss 
Microimaging, GmbH, Oberkochen, Germany) at a magnification of 40×. Fluorescence was quantified using the 
Volocity software (PerkinElmer, Waltham, MA, USA).
Measurement of mitochondrial membrane potential (ΔΨm). ΔΨm was measured as was 
described previously83. Briefly, cells plated on 25 mm laminin-coated coverslips and loaded with 40 nM 
tetramethyl-rhodamine methyl ester (TMRM) in a HEPES-buffered salt solution (HBSS) (composed of 156 mM 
NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM glucose and 10 mM HEPES; pH adjusted 
to 7.35 with NaOH) for 40 min at room temperature and keeping the dye present in the chamber at the time of 
recording. TMRM is a cell-permeant fluorescent dye used in the redistribution mode to assess ΔΨm, and there-
fore, a reduction in TMRM fluorescence represents mitochondrial depolarisation. Confocal images were obtained 
using a Zeiss 510 microscope equipped with META detection system (Zeiss, Oberkochen, Germany) and × 40 
oil immersion objective. Excitation wavelength for TMRM was 560 nm and emission was detected above 580 nm. 
Z-stack images were obtained and analysed using the Volocity software (PerkinElmer, Waltham, MA, USA) and 
TMRM values for untreated cells were set to 100%. TMRM values for Aβ42 and/or annexin A5 treated cells were 
expressed relative to untreated cells.
Imaging of [Ca2+]c. For cytosolic [Ca2+] ([Ca2+]c) measurements cells were plated on 25 mm laminin-coated 
coverslips and maintained in DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine and 1% penicillin/
streptomycin at 37 °C and 5% CO2. After 5–7 days on culture, media was replaced with HBSS (156 mM NaCl, 
3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM glucose and 10 mM HEPES, pH adjusted to 
7.35) and cells were loaded with fura-2 AM (5 µM; Molecular Probes, Thermo Fisher Scientific, MA, USA) and 
0.005% pluronic for 30 minutes. For simultaneous measurement of [Ca2+]c and ΔΨm, rhodamine123 (Rh123, 
10 μM; Molecular Probes, Thermo Fisher Scientific, MA, USA) was added into the cultures during the last 15 min 
of the fura-2 loading period, and cells were then washed. We stimulated P2Y receptors from choroid plexus 
cells with 100 μM ATP and we added 1 µM carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) to 
depolarise mitochondria. Fluorescence measurements were obtained on an epifluorescence inverted microscope 
equipped with a × 20 fluorite objective. Simultaneous [Ca2+]c and ΔΨm were monitored in single cells using 
excitation light provided by a Xenon arc lamp, the beam passing sequentially through 10 nm band pass filters 
centred at 340, 380 and 490 nm housed in computer-controlled filter wheel (Cairn Research, Kent, UK). Emitted 
fluorescence light was reflected through a 515 nm long-pass filter to a cooled CCD camera (Retiga, QImaging, 
Canada). All imaging data were collected and analysed using the Andor software (Belfast, UK). The fura-2 data 
were not calibrated in terms of [Ca2+]c because of the uncertainty arising from the use of different calibration 
techniques. The fluorescent signal is quenched by Rh123 accumulation in polarised mitochondria; in response to 
depolarisation the fluorescence signal is dequenched; an increase in Rh123 signal therefore indicates mitochon-
drial depolarisation. We normalised the signals between resting level (set to 0) and a maximal signal generated in 
response to the uncoupler FCCP (1 μM; set to 100%).
Data and statistical analysis. In vivo and in vitro results are shown related to healthy donors and untreated 
cells, respectively. All of them are expressed as mean ± standard error of the mean (SEM) in percentage. In vitro 
data were generated from a minimum of three independent replicates per experiment (n = 3) performed in dif-
ferent days. For in vivo imaging, each replicate consisted of at least 1 coverslip per condition where a number of 
15–30 cells per coverslip were analysed. Statistical analysis and exponential curve fitting were performed using 
GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA) software. Grubbs outlier filter was used for all data. 
Statistical significance for multiple comparisons was calculated by one-way ANOVA followed by Fisher’s LSD 
correction. In all cases, statistical significance was set at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001; (#p < 0.05, 
##p < 0.01, ###p < 0.001, ####p < 0.0001).
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Ethical approval and informed consent. All participants gave written informed consent for participa-
tion. ARRIVA guidelines for the care and use of animals were followed. The project in full was approved by the 12 
de Octubre Research Institute ethical review committee. Additionally, research related to CSF samples was also 
approved by the 12 de Octubre Hospital, (Madrid, Spain) and Hospital de la Santa Creu i Sant Pau (Barcelona, 
Spain) review committees; research involving the use of choroid plexus samples from human donors was also 
approved by the Institute of Neuropathology Brain Bank IDIBELL-Hospital Universitari de Bellvitge (Hospitalet 
de Llobregat, Spain) review committee, The Netherlands Brain Bank (NBB) (Amsterdam, The Nederlands) review 
committee and Banco de Tejidos, Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas, 
Madrid. Spain) review committee.
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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